<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kawaguchi R</submitter><funding>Japan Science and Technology Agency</funding><funding>Japan Society for the Promotion of Science</funding><pagination>BSR20253768</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12905485</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>46(1)</volume><pubmed_abstract>Hyperhomocysteinemia is a risk factor of cardiovascular disease (CVD). High-density lipoprotein (HDL) plays an important role in anti-atherosclerosis, with its anti-atherogenic function attributed to HDL-associated proteins such as apolipoprotein A-I (apoA-I) and paraoxonase 1 (PON1). Homocysteine (Hcy) thiolactone modifies lysine residues in proteins, thereby altering their function. Although dysfunction of apoA-I and PON1 has been reported, the precise modification sites and underlying mechanisms have remained unclear. In this study, we aimed to identify Hcy-thiolactone modification sites on apoA-I and PON1. In addition, we sought to clarify the effects of Hcy-thiolactone on PON1 activity and its distribution. Modification sites were analyzed using MALDI-TOF MS. The effects of Hcy-thiola</pubmed_abstract><journal>Bioscience reports</journal><pubmed_title>Homocysteine thiolactone affects paraoxonase 1 activity via altered paraoxonase 1 distribution on high-density lipoprotein particles.</pubmed_title><pmcid>PMC12905485</pmcid><funding_grant_id>22K07466, 25K10657</funding_grant_id><funding_grant_id>JPMJSP2120</funding_grant_id><pubmed_authors>Kugii Y</pubmed_authors><pubmed_authors>Ohkawa R</pubmed_authors><pubmed_authors>Hosoya S</pubmed_authors><pubmed_authors>Suzuki N</pubmed_authors><pubmed_authors>Kawaguchi R</pubmed_authors><pubmed_authors>Sasaki T</pubmed_authors><pubmed_authors>Miyakoshi T</pubmed_authors><pubmed_authors>Yoshimoto A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Homocysteine thiolactone affects paraoxonase 1 activity via altered paraoxonase 1 distribution on high-density lipoprotein particles.</name><description>Hyperhomocysteinemia is a risk factor of cardiovascular disease (CVD). High-density lipoprotein (HDL) plays an important role in anti-atherosclerosis, with its anti-atherogenic function attributed to HDL-associated proteins such as apolipoprotein A-I (apoA-I) and paraoxonase 1 (PON1). Homocysteine (Hcy) thiolactone modifies lysine residues in proteins, thereby altering their function. Although dysfunction of apoA-I and PON1 has been reported, the precise modification sites and underlying mechanisms have remained unclear. In this study, we aimed to identify Hcy-thiolactone modification sites on apoA-I and PON1. In addition, we sought to clarify the effects of Hcy-thiolactone on PON1 activity and its distribution. Modification sites were analyzed using MALDI-TOF MS. The effects of Hcy-thiola</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-07-15T16:28:58.944Z</modification><creation>2026-07-07T03:08:11.901Z</creation></dates><accession>S-EPMC12905485</accession><cross_references><pubmed>41496561</pubmed><doi>10.1042/BSR20253768</doi></cross_references></HashMap>